Efficacy and Safety of Aripiprazole in Borderline Personality Disorder: A Systematic Review
Aripiprazole is an atypical antipsychotic medication, and its use in treating borderline personality disorder (BPD) is debatable because it is not FDA-approved for treating BPD. This study aimed to investigate the efficacy and safety of aripiprazole in patients with BPD. On July 2, 2021, the protoco...
Gespeichert in:
| Veröffentlicht in: | Psychiatric quarterly 2023-12, Vol.94 (4), p.541-557 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 557 |
|---|---|
| container_issue | 4 |
| container_start_page | 541 |
| container_title | Psychiatric quarterly |
| container_volume | 94 |
| creator | Valdivieso-Jiménez, Glauco Pino-Zavaleta, Dennis Anthony Campos-Rodriguez, Susan K. Ortiz-Saavedra, Brando Fernández, María F. Benites-Zapata, Vicente Aleixandre |
| description | Aripiprazole is an atypical antipsychotic medication, and its use in treating borderline personality disorder (BPD) is debatable because it is not FDA-approved for treating BPD. This study aimed to investigate the efficacy and safety of aripiprazole in patients with BPD. On July 2, 2021, the protocol (CRD42021256647) was registered in PROSPERO. PubMed, Scopus, Web of Science, Ovid-Medline, Embase, PsycINFO, and Cochrane (CENTRAL) were searched without regard for language or publication date. We also searched trial registries on ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform. Randomized clinical trials with adult patients diagnosed with BPD met the inclusion criteria. The Cochrane risk of bias for randomized trials (RoB-2) method was used to assess the quality of the included studies. We included two previously published randomized clinical trials. There were 76 patients with BPD, with 38, 12, and 26 assigned to the aripiprazole, olanzapine, and placebo groups, respectively. Most patients (88.16%) were females, with ages ranging from 22.1 to 28.14 yr. Aripiprazole has been proven to reduce anxiety, depression, anger, hostility, clinical severity, and obsessive–compulsive behavior, insecurity, melancholy, anxiety, aggressiveness/hostility, phobic anxiety, paranoid thinking, psychoticism, and somatization. The adverse effects were headache, insomnia, restlessness, tremor, and akathisia. The risk of bias was considerable in both trials, which is somewhat problematic considering that prejudice can lead to incorrect outcomes and conclusions. Aripiprazole has demonstrated encouraging outcomes in the treatment of patients with BPD. More randomized controlled studies are needed. |
| doi_str_mv | 10.1007/s11126-023-10045-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2850311326</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2850311326</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-a6b80de402ac862c1c6947c49327adf89e3e5d6686ea6a511849bacd6cbdd24b3</originalsourceid><addsrcrecordid>eNp9kMlOwzAQhi0EgrK8AAdkiQuXgJfEcbiVUhYJCUThxMFy7AkySpNiJ6Dy9Lgti8SB08iab_4ZfwjtU3JMCclPAqWUiYQwnsR3miVyDQ1olvNE5KRYRwNCOE9YzsgW2g7hhRBKBWebaIvnmRBM0AF6GleVM9rMsW4snugKujluKzz0buZmXn-0NWDX4LPWW_C1awDfgQ9to2sXyXMXlo1TPMSTeehgqjtn8D28OXjfRRuVrgPsfdUd9HgxfhhdJTe3l9ej4U1i4h1dokUpiYWUMG2kYIYaUaS5SQvOcm0rWQCHzAohBWihM0plWpTaWGFKa1la8h10tMqd-fa1h9CpqQsG6lo30PZBMZkRTilnIqKHf9CXtvfxMwtKylRmRc4ixVaU8W0IHio1826q_VxRohbq1Uq9iurVUr2ScejgK7ovp2B_Rr5dR4CvgBBbzTP4393_xH4C-JuOVg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2888485972</pqid></control><display><type>article</type><title>Efficacy and Safety of Aripiprazole in Borderline Personality Disorder: A Systematic Review</title><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>SpringerLink Journals - AutoHoldings</source><creator>Valdivieso-Jiménez, Glauco ; Pino-Zavaleta, Dennis Anthony ; Campos-Rodriguez, Susan K. ; Ortiz-Saavedra, Brando ; Fernández, María F. ; Benites-Zapata, Vicente Aleixandre</creator><creatorcontrib>Valdivieso-Jiménez, Glauco ; Pino-Zavaleta, Dennis Anthony ; Campos-Rodriguez, Susan K. ; Ortiz-Saavedra, Brando ; Fernández, María F. ; Benites-Zapata, Vicente Aleixandre</creatorcontrib><description>Aripiprazole is an atypical antipsychotic medication, and its use in treating borderline personality disorder (BPD) is debatable because it is not FDA-approved for treating BPD. This study aimed to investigate the efficacy and safety of aripiprazole in patients with BPD. On July 2, 2021, the protocol (CRD42021256647) was registered in PROSPERO. PubMed, Scopus, Web of Science, Ovid-Medline, Embase, PsycINFO, and Cochrane (CENTRAL) were searched without regard for language or publication date. We also searched trial registries on ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform. Randomized clinical trials with adult patients diagnosed with BPD met the inclusion criteria. The Cochrane risk of bias for randomized trials (RoB-2) method was used to assess the quality of the included studies. We included two previously published randomized clinical trials. There were 76 patients with BPD, with 38, 12, and 26 assigned to the aripiprazole, olanzapine, and placebo groups, respectively. Most patients (88.16%) were females, with ages ranging from 22.1 to 28.14 yr. Aripiprazole has been proven to reduce anxiety, depression, anger, hostility, clinical severity, and obsessive–compulsive behavior, insecurity, melancholy, anxiety, aggressiveness/hostility, phobic anxiety, paranoid thinking, psychoticism, and somatization. The adverse effects were headache, insomnia, restlessness, tremor, and akathisia. The risk of bias was considerable in both trials, which is somewhat problematic considering that prejudice can lead to incorrect outcomes and conclusions. Aripiprazole has demonstrated encouraging outcomes in the treatment of patients with BPD. More randomized controlled studies are needed.</description><identifier>ISSN: 0033-2720</identifier><identifier>EISSN: 1573-6709</identifier><identifier>DOI: 10.1007/s11126-023-10045-8</identifier><identifier>PMID: 37566261</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Aggressive behavior ; Akathisia ; Antipsychotics ; Anxiety ; Aripiprazole ; Bias ; Borderline personality disorder ; Clinical research ; Clinical trials ; Compulsions ; Drugs ; Efficacy ; Hostility ; Insecurity ; Insomnia ; Medicine ; Medicine & Public Health ; Obsessive compulsive disorder ; Olanzapine ; Paranoia ; Patients ; Personality ; Personality disorders ; Phobic anxiety ; Prejudice ; Psychiatry ; Psychosis ; Public Health ; Restlessness ; Review Article ; Sadness ; Safety ; Side effects ; Sleep disorders ; Sociology ; Somatization ; Systematic review ; Tremor</subject><ispartof>Psychiatric quarterly, 2023-12, Vol.94 (4), p.541-557</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-a6b80de402ac862c1c6947c49327adf89e3e5d6686ea6a511849bacd6cbdd24b3</citedby><cites>FETCH-LOGICAL-c375t-a6b80de402ac862c1c6947c49327adf89e3e5d6686ea6a511849bacd6cbdd24b3</cites><orcidid>0000-0003-1201-2984 ; 0000-0001-5733-5176 ; 0000-0002-8932-8437 ; 0000-0001-8561-6768 ; 0000-0002-9158-1108 ; 0000-0002-1606-3570</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11126-023-10045-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11126-023-10045-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,12846,27924,27925,30999,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37566261$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Valdivieso-Jiménez, Glauco</creatorcontrib><creatorcontrib>Pino-Zavaleta, Dennis Anthony</creatorcontrib><creatorcontrib>Campos-Rodriguez, Susan K.</creatorcontrib><creatorcontrib>Ortiz-Saavedra, Brando</creatorcontrib><creatorcontrib>Fernández, María F.</creatorcontrib><creatorcontrib>Benites-Zapata, Vicente Aleixandre</creatorcontrib><title>Efficacy and Safety of Aripiprazole in Borderline Personality Disorder: A Systematic Review</title><title>Psychiatric quarterly</title><addtitle>Psychiatr Q</addtitle><addtitle>Psychiatr Q</addtitle><description>Aripiprazole is an atypical antipsychotic medication, and its use in treating borderline personality disorder (BPD) is debatable because it is not FDA-approved for treating BPD. This study aimed to investigate the efficacy and safety of aripiprazole in patients with BPD. On July 2, 2021, the protocol (CRD42021256647) was registered in PROSPERO. PubMed, Scopus, Web of Science, Ovid-Medline, Embase, PsycINFO, and Cochrane (CENTRAL) were searched without regard for language or publication date. We also searched trial registries on ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform. Randomized clinical trials with adult patients diagnosed with BPD met the inclusion criteria. The Cochrane risk of bias for randomized trials (RoB-2) method was used to assess the quality of the included studies. We included two previously published randomized clinical trials. There were 76 patients with BPD, with 38, 12, and 26 assigned to the aripiprazole, olanzapine, and placebo groups, respectively. Most patients (88.16%) were females, with ages ranging from 22.1 to 28.14 yr. Aripiprazole has been proven to reduce anxiety, depression, anger, hostility, clinical severity, and obsessive–compulsive behavior, insecurity, melancholy, anxiety, aggressiveness/hostility, phobic anxiety, paranoid thinking, psychoticism, and somatization. The adverse effects were headache, insomnia, restlessness, tremor, and akathisia. The risk of bias was considerable in both trials, which is somewhat problematic considering that prejudice can lead to incorrect outcomes and conclusions. Aripiprazole has demonstrated encouraging outcomes in the treatment of patients with BPD. More randomized controlled studies are needed.</description><subject>Aggressive behavior</subject><subject>Akathisia</subject><subject>Antipsychotics</subject><subject>Anxiety</subject><subject>Aripiprazole</subject><subject>Bias</subject><subject>Borderline personality disorder</subject><subject>Clinical research</subject><subject>Clinical trials</subject><subject>Compulsions</subject><subject>Drugs</subject><subject>Efficacy</subject><subject>Hostility</subject><subject>Insecurity</subject><subject>Insomnia</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Obsessive compulsive disorder</subject><subject>Olanzapine</subject><subject>Paranoia</subject><subject>Patients</subject><subject>Personality</subject><subject>Personality disorders</subject><subject>Phobic anxiety</subject><subject>Prejudice</subject><subject>Psychiatry</subject><subject>Psychosis</subject><subject>Public Health</subject><subject>Restlessness</subject><subject>Review Article</subject><subject>Sadness</subject><subject>Safety</subject><subject>Side effects</subject><subject>Sleep disorders</subject><subject>Sociology</subject><subject>Somatization</subject><subject>Systematic review</subject><subject>Tremor</subject><issn>0033-2720</issn><issn>1573-6709</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>7QJ</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kMlOwzAQhi0EgrK8AAdkiQuXgJfEcbiVUhYJCUThxMFy7AkySpNiJ6Dy9Lgti8SB08iab_4ZfwjtU3JMCclPAqWUiYQwnsR3miVyDQ1olvNE5KRYRwNCOE9YzsgW2g7hhRBKBWebaIvnmRBM0AF6GleVM9rMsW4snugKujluKzz0buZmXn-0NWDX4LPWW_C1awDfgQ9to2sXyXMXlo1TPMSTeehgqjtn8D28OXjfRRuVrgPsfdUd9HgxfhhdJTe3l9ej4U1i4h1dokUpiYWUMG2kYIYaUaS5SQvOcm0rWQCHzAohBWihM0plWpTaWGFKa1la8h10tMqd-fa1h9CpqQsG6lo30PZBMZkRTilnIqKHf9CXtvfxMwtKylRmRc4ixVaU8W0IHio1826q_VxRohbq1Uq9iurVUr2ScejgK7ovp2B_Rr5dR4CvgBBbzTP4393_xH4C-JuOVg</recordid><startdate>20231201</startdate><enddate>20231201</enddate><creator>Valdivieso-Jiménez, Glauco</creator><creator>Pino-Zavaleta, Dennis Anthony</creator><creator>Campos-Rodriguez, Susan K.</creator><creator>Ortiz-Saavedra, Brando</creator><creator>Fernández, María F.</creator><creator>Benites-Zapata, Vicente Aleixandre</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7QJ</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HEHIP</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2S</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1201-2984</orcidid><orcidid>https://orcid.org/0000-0001-5733-5176</orcidid><orcidid>https://orcid.org/0000-0002-8932-8437</orcidid><orcidid>https://orcid.org/0000-0001-8561-6768</orcidid><orcidid>https://orcid.org/0000-0002-9158-1108</orcidid><orcidid>https://orcid.org/0000-0002-1606-3570</orcidid></search><sort><creationdate>20231201</creationdate><title>Efficacy and Safety of Aripiprazole in Borderline Personality Disorder: A Systematic Review</title><author>Valdivieso-Jiménez, Glauco ; Pino-Zavaleta, Dennis Anthony ; Campos-Rodriguez, Susan K. ; Ortiz-Saavedra, Brando ; Fernández, María F. ; Benites-Zapata, Vicente Aleixandre</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-a6b80de402ac862c1c6947c49327adf89e3e5d6686ea6a511849bacd6cbdd24b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Aggressive behavior</topic><topic>Akathisia</topic><topic>Antipsychotics</topic><topic>Anxiety</topic><topic>Aripiprazole</topic><topic>Bias</topic><topic>Borderline personality disorder</topic><topic>Clinical research</topic><topic>Clinical trials</topic><topic>Compulsions</topic><topic>Drugs</topic><topic>Efficacy</topic><topic>Hostility</topic><topic>Insecurity</topic><topic>Insomnia</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Obsessive compulsive disorder</topic><topic>Olanzapine</topic><topic>Paranoia</topic><topic>Patients</topic><topic>Personality</topic><topic>Personality disorders</topic><topic>Phobic anxiety</topic><topic>Prejudice</topic><topic>Psychiatry</topic><topic>Psychosis</topic><topic>Public Health</topic><topic>Restlessness</topic><topic>Review Article</topic><topic>Sadness</topic><topic>Safety</topic><topic>Side effects</topic><topic>Sleep disorders</topic><topic>Sociology</topic><topic>Somatization</topic><topic>Systematic review</topic><topic>Tremor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Valdivieso-Jiménez, Glauco</creatorcontrib><creatorcontrib>Pino-Zavaleta, Dennis Anthony</creatorcontrib><creatorcontrib>Campos-Rodriguez, Susan K.</creatorcontrib><creatorcontrib>Ortiz-Saavedra, Brando</creatorcontrib><creatorcontrib>Fernández, María F.</creatorcontrib><creatorcontrib>Benites-Zapata, Vicente Aleixandre</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection【Remote access available】</collection><collection>ProQuest Central (Corporate)</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Social Science Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>Sociology Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Psychology Database</collection><collection>ProQuest Research Library</collection><collection>Sociology Database</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Psychiatric quarterly</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Valdivieso-Jiménez, Glauco</au><au>Pino-Zavaleta, Dennis Anthony</au><au>Campos-Rodriguez, Susan K.</au><au>Ortiz-Saavedra, Brando</au><au>Fernández, María F.</au><au>Benites-Zapata, Vicente Aleixandre</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and Safety of Aripiprazole in Borderline Personality Disorder: A Systematic Review</atitle><jtitle>Psychiatric quarterly</jtitle><stitle>Psychiatr Q</stitle><addtitle>Psychiatr Q</addtitle><date>2023-12-01</date><risdate>2023</risdate><volume>94</volume><issue>4</issue><spage>541</spage><epage>557</epage><pages>541-557</pages><issn>0033-2720</issn><eissn>1573-6709</eissn><abstract>Aripiprazole is an atypical antipsychotic medication, and its use in treating borderline personality disorder (BPD) is debatable because it is not FDA-approved for treating BPD. This study aimed to investigate the efficacy and safety of aripiprazole in patients with BPD. On July 2, 2021, the protocol (CRD42021256647) was registered in PROSPERO. PubMed, Scopus, Web of Science, Ovid-Medline, Embase, PsycINFO, and Cochrane (CENTRAL) were searched without regard for language or publication date. We also searched trial registries on ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform. Randomized clinical trials with adult patients diagnosed with BPD met the inclusion criteria. The Cochrane risk of bias for randomized trials (RoB-2) method was used to assess the quality of the included studies. We included two previously published randomized clinical trials. There were 76 patients with BPD, with 38, 12, and 26 assigned to the aripiprazole, olanzapine, and placebo groups, respectively. Most patients (88.16%) were females, with ages ranging from 22.1 to 28.14 yr. Aripiprazole has been proven to reduce anxiety, depression, anger, hostility, clinical severity, and obsessive–compulsive behavior, insecurity, melancholy, anxiety, aggressiveness/hostility, phobic anxiety, paranoid thinking, psychoticism, and somatization. The adverse effects were headache, insomnia, restlessness, tremor, and akathisia. The risk of bias was considerable in both trials, which is somewhat problematic considering that prejudice can lead to incorrect outcomes and conclusions. Aripiprazole has demonstrated encouraging outcomes in the treatment of patients with BPD. More randomized controlled studies are needed.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>37566261</pmid><doi>10.1007/s11126-023-10045-8</doi><tpages>17</tpages><orcidid>https://orcid.org/0000-0003-1201-2984</orcidid><orcidid>https://orcid.org/0000-0001-5733-5176</orcidid><orcidid>https://orcid.org/0000-0002-8932-8437</orcidid><orcidid>https://orcid.org/0000-0001-8561-6768</orcidid><orcidid>https://orcid.org/0000-0002-9158-1108</orcidid><orcidid>https://orcid.org/0000-0002-1606-3570</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0033-2720 |
| ispartof | Psychiatric quarterly, 2023-12, Vol.94 (4), p.541-557 |
| issn | 0033-2720 1573-6709 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2850311326 |
| source | Applied Social Sciences Index & Abstracts (ASSIA); SpringerLink Journals - AutoHoldings |
| subjects | Aggressive behavior Akathisia Antipsychotics Anxiety Aripiprazole Bias Borderline personality disorder Clinical research Clinical trials Compulsions Drugs Efficacy Hostility Insecurity Insomnia Medicine Medicine & Public Health Obsessive compulsive disorder Olanzapine Paranoia Patients Personality Personality disorders Phobic anxiety Prejudice Psychiatry Psychosis Public Health Restlessness Review Article Sadness Safety Side effects Sleep disorders Sociology Somatization Systematic review Tremor |
| title | Efficacy and Safety of Aripiprazole in Borderline Personality Disorder: A Systematic Review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T16%3A19%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20Safety%20of%20Aripiprazole%20in%20Borderline%20Personality%20Disorder:%20A%20Systematic%20Review&rft.jtitle=Psychiatric%20quarterly&rft.au=Valdivieso-Jim%C3%A9nez,%20Glauco&rft.date=2023-12-01&rft.volume=94&rft.issue=4&rft.spage=541&rft.epage=557&rft.pages=541-557&rft.issn=0033-2720&rft.eissn=1573-6709&rft_id=info:doi/10.1007/s11126-023-10045-8&rft_dat=%3Cproquest_cross%3E2850311326%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2888485972&rft_id=info:pmid/37566261&rfr_iscdi=true |